rationale NUMBER iss synthetic oligonucleotide containing immunostimulatory cpg motifs animal studies NUMBER iss effectively inhibited lung inflammation including eosinophil infiltration airway hyperresponsiveness objectives evaluate NUMBER iss activity subjects allergic asthma methods subjects n NUMBER NUMBER iss n NUMBER placebo enrolled randomized placebocontrolled study examine safety pharmacologic activity efficacy NUMBER iss airway responses subjects received NUMBER mg NUMBER iss placebo nebulization weekly NUMBER wk measurements allergen inhalation challenge performed NUMBER h 2nd 4th doses measure early late fall fev1 sputum cells peripheral blood mononuclear cells collected dosing gene expression measured quantitative polymerase chain reaction main results treatment NUMBER iss significantly increased expression interferon genes NUMBER kd protein ip10 monokine induced mig gene monocyte chemotactic protein cells collected postdose p NUMBER attenuation early late decrease fev1 NUMBER iss compared placebo reduction sputum eosinophils gene expression measured sputum cells conclusions study demonstrated NUMBER iss safe pharmacologically active respiratory tract asthmatics dose regimen did inhibit fall fev1 key features response inhaled allergen challenge suggests induction ifn genes sufficient inhibit responses asthmatic subjects th2 mediated double blind parallel group allergen induced ifn gamma ifn inducible ifn gamma inducible ifn gamma ifn stimulated isg NUMBER mcp NUMBER mcp NUMBER allergen induced th2 related ifn inducible allergen induced